Scientific Poster Download

The continued evolution of antibody-drug conjugates (ADCs) and emerging antibody-based conjugates requires conjugation technologies capable of precise payload control, molecular homogeneity, and manufacturing scalability.
 
WuXiDARx™ is a precision conjugation platform that enables sequential loading of payload-linkers onto native antibodyinterchain cysteines without antibody engineering or enzymatic conjugation, supporting diverse ADC and XDC modalitieswith versatile DAR selections (e.g., 1, 2, 4, 6). To date, WuXiDAR4™-based ADCs have supported over 10 CMC programs,including 8 clinical-stage molecules, with manufacturing demonstrated at scales exceeding 2 kg.
 
In this scientific poster, we highlight core applications and extended capabilities of the WuXiDARx™ platform. The platform supports the rational design of dual-payload ADCs (dp-ADCs) to overcome tumor heterogeneity and payload resistance via payloads with complementary mechanisms of action. Integration with hydrophilic WuXi Payload-Linker™ technology enables the production of homogeneous 4+4, 2+4, and 2+6 dp-ADC formats with precise payload composition control. Beyond ADCs, WuXiDARx™ accommodates emerging XDC modalities: WuXiDAR1™ generates homogeneous antibody-oligonucleotide conjugates with controlled single-oligonucleotide loading, while WuXiDAR2™ enables site-selective antibody-peptide conjugates with defined peptide loading. WuXiDARx™ therefore serves as a unified platform for developing next-generation ADCs and XDCs with accurate control of payload identity, loading, and molecular architecture.